A Phase 2 clinical trial of GDC-0310 for the treatment of pain
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2017
Price : $35 *
At a glance
- Drugs GDC 0310 (Primary)
- Indications Pain
- Focus Therapeutic Use
- 07 Nov 2017 According to a Xenon Pharmaceuticals media release, based on the data from ongoing pre-clinical toxicology studies the company has decided to postpone the initiation of this trial. Future development will be updated once the pre-clinical studies are completed and the final results are analyzed.
- 03 Aug 2017 According to a Xenon Pharmaceuticals media release, the company plans to initiate this study in the first quarter of 2018.
- 11 Mar 2017 New trial record